Age

19–64

Sex

ALL

Healthy volunteers

Accepted

Healthy adult volunteers aged ≥19 and \<65 years at the time of the screening visit
Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit

Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
Other exclusions applied

Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322